The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar

Date: 01st September, 2026 The Manager Corporate Relationship Department, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400001 Scrip Code: 544759, Scrip ID: GLPL Subject: - Disclosures under Regulation 29 of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 Dear Sir/Madam, This is to inform you that pursuant to Regulation 29(2) of SEBI (SAST) Regulation, 2011, the Company has received a disclosure pursuant to acquisition of equity shares from the open market is as follows: SR Name of the Disclosure dated/ No of shares Remarks No Acquirer Regulation purchased and % of total issued and paid- up share Capital 1. Mr. Disclosure dated Acquired 60000 equity Mr. Amol Laxmikant Amol 31st August, 2026 shares representing Mujumdar, Promoter and Laxmikant pursuant to (0.62%) of the total Managing Director of the Mujumdar Regulation 29(2) issued and paid-up share Company have acquired of SEBI (SAST) capital of the Company 60000 equity shares as on Regulation, 2011 31.08.2026 through open market. We request you to kindly take the above disclosure on your records. Thanking You, Yours faithfully, For Goldline Pharmaceutical Limited R uchi Sanket Modi Company Secretary cum Compliance Officer